Oritavancin in vitro activity against the most prevalent antibiogram resistance patterns among MRSA, including MDR strains from patients in European hospitals (2010-2013)
Oritavancin in vitro activity against the most prevalent antibiogram resistance patterns among MRSA, including MDR strains from patients in European hospitals (2010-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
